44 related articles for article (PubMed ID: 12950266)
1. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
Williams NS; Burgett AW; Atkins AS; Wang X; Harran PG; McKnight SL
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2074-9. PubMed ID: 17287337
[TBL] [Abstract][Full Text] [Related]
3. Bridging the maytansine and vinca sites: cryptophycins target β-tubulin's T5-loop.
Abel AC; Mühlethaler T; Dessin C; Schachtsiek T; Sammet B; Sharpe T; Steinmetz MO; Sewald N; Prota AE
J Biol Chem; 2024 May; ():107363. PubMed ID: 38735475
[TBL] [Abstract][Full Text] [Related]
4. Marine mollusc derived dolastatin 10 peptide: a potential therapeutic agent for oral cancer.
Ramasamy P
Nat Prod Res; 2024 May; ():1-2. PubMed ID: 38738701
[No Abstract] [Full Text] [Related]
5. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
6. Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.
Bailon-Moscoso N; Cevallos-Solorzano G; Romero-Benavides JC; Orellana MI
Curr Genomics; 2017 Apr; 18(2):106-131. PubMed ID: 28367072
[TBL] [Abstract][Full Text] [Related]
7. From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides.
Blanco-Míguez A; Gutiérrez-Jácome A; Pérez-Pérez M; Pérez-Rodríguez G; Catalán-García S; Fdez-Riverola F; Lourenço A; Sánchez B
Protein Sci; 2016 Jun; 25(6):1084-95. PubMed ID: 27010507
[TBL] [Abstract][Full Text] [Related]
8. Antimitotic drugs in the treatment of cancer.
van Vuuren RJ; Visagie MH; Theron AE; Joubert AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1101-12. PubMed ID: 26563258
[TBL] [Abstract][Full Text] [Related]
9. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V
Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003
[TBL] [Abstract][Full Text] [Related]
10. CHROMATOGRAPHIC ANALYSIS OF DRUG INTERACTIONS IN THE SERUM PROTEOME.
Hage DS; Anguizola JA; Jackson AJ; Matsuda R; Papastavros E; Pfaunmiller E; Tong Z; Vargas-Badilla J; Yoo MJ; Zheng X
Anal Methods; 2011 Jul; 3(7):. PubMed ID: 24223625
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs.
Lopus M
Mol Cell Biochem; 2013 Oct; 382(1-2):93-102. PubMed ID: 23744533
[TBL] [Abstract][Full Text] [Related]
12. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
Rai A; Surolia A; Panda D
PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
[TBL] [Abstract][Full Text] [Related]
13. Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces.
Sackett DL; Fojo T
Cell Cycle; 2011 Oct; 10(19):3233-4. PubMed ID: 21946521
[No Abstract] [Full Text] [Related]
14. Impact of marine drugs on cytoskeleton-mediated reproductive events.
Silvestre F; Tosti E
Mar Drugs; 2010 Mar; 8(4):881-915. PubMed ID: 20479959
[TBL] [Abstract][Full Text] [Related]
15. High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic (-)-pironetin and analogs.
Vogt A; McPherson PA; Shen X; Balachandran R; Zhu G; Raccor BS; Nelson SG; Tsang M; Day BW
Chem Biol Drug Des; 2009 Oct; 74(4):358-68. PubMed ID: 19691472
[TBL] [Abstract][Full Text] [Related]
16. Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides.
Hopkins CD; Wipf P
Nat Prod Rep; 2009 May; 26(5):585-601. PubMed ID: 19387496
[TBL] [Abstract][Full Text] [Related]
17. Diazonamide support studies: stereoselective formation of the C10 chiral center in both the CDEFG and AEFG fragments.
Lin J; Gerstenberger BS; Stessman NY; Konopelski JP
Org Lett; 2008 Sep; 10(18):3969-72. PubMed ID: 18702502
[TBL] [Abstract][Full Text] [Related]
18. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
19. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
